DK2011796T3 - Neurogenese-inducer eller terapeutisk middel mod neuropati omfattende alkyletherderivat eller salt deraf - Google Patents

Neurogenese-inducer eller terapeutisk middel mod neuropati omfattende alkyletherderivat eller salt deraf

Info

Publication number
DK2011796T3
DK2011796T3 DK07742276.4T DK07742276T DK2011796T3 DK 2011796 T3 DK2011796 T3 DK 2011796T3 DK 07742276 T DK07742276 T DK 07742276T DK 2011796 T3 DK2011796 T3 DK 2011796T3
Authority
DK
Denmark
Prior art keywords
neurogenese
alkyletheric
induces
derivatives
salts
Prior art date
Application number
DK07742276.4T
Other languages
English (en)
Inventor
Noboru Iwakami
Shigeki Marubuchi
Tomohiro Okuda
Original Assignee
Toyama Chemical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Toyama Chemical Co Ltd filed Critical Toyama Chemical Co Ltd
Application granted granted Critical
Publication of DK2011796T3 publication Critical patent/DK2011796T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
DK07742276.4T 2006-04-26 2007-04-24 Neurogenese-inducer eller terapeutisk middel mod neuropati omfattende alkyletherderivat eller salt deraf DK2011796T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2006122080 2006-04-26
PCT/JP2007/058841 WO2007125913A1 (ja) 2006-04-26 2007-04-24 アルキルエーテル誘導体またはその塩を含有する神経細胞新生誘導剤および精神障害治療剤

Publications (1)

Publication Number Publication Date
DK2011796T3 true DK2011796T3 (da) 2014-10-27

Family

ID=38655439

Family Applications (1)

Application Number Title Priority Date Filing Date
DK07742276.4T DK2011796T3 (da) 2006-04-26 2007-04-24 Neurogenese-inducer eller terapeutisk middel mod neuropati omfattende alkyletherderivat eller salt deraf

Country Status (20)

Country Link
US (1) US20090093453A1 (da)
EP (1) EP2011796B1 (da)
JP (2) JP5695293B2 (da)
KR (1) KR101374593B1 (da)
CN (1) CN101432280B (da)
AU (1) AU2007244409B2 (da)
BR (1) BRPI0710239A2 (da)
CA (1) CA2648898C (da)
CY (1) CY1115643T1 (da)
DK (1) DK2011796T3 (da)
ES (1) ES2518371T3 (da)
IL (1) IL194569A (da)
MX (1) MX2008013728A (da)
NO (1) NO342153B1 (da)
NZ (1) NZ571975A (da)
PL (1) PL2011796T3 (da)
PT (1) PT2011796E (da)
SI (1) SI2011796T1 (da)
WO (1) WO2007125913A1 (da)
ZA (1) ZA200808728B (da)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0213393B8 (pt) 2001-10-19 2021-05-25 Fujifilm Toyama Chemical Co Ltd derivados de éter alquílico, ou um de seus sais, processo para produzir um derivado de éter alquílico, derivado de alquil-amida, ou um de seus sais, e, composição farmacêutica
HUE041842T2 (hu) 2002-06-14 2019-05-28 Toyama Chemical Co Ltd Gyógyászati készítmény agymûködés javítására
SI2248809T1 (sl) * 2005-03-28 2012-09-28 Toyama Chemical Co Ltd Alkil-3-(2-(benzo(b)tiofen-5-il)-etoksi)-propanoati kot vmesniki v proizvodnji derivatov azetidin-3-ola
CA2659835A1 (en) * 2006-08-04 2008-02-07 Toyama Chemical Co., Ltd. Protein kinase c activity enhancer containing alkyl ether derivative or salt thereof
MX2010012787A (es) 2008-05-28 2011-02-24 Toyama Chemical Co Ltd Nuevo derivado de oxido de benzotiofeno y sal del mismo.
RU2673489C2 (ru) * 2013-09-12 2018-11-27 Ф. Хоффманн-Ля Рош Аг Производные индолкарбоксамида
BR112016017747A2 (pt) * 2014-01-31 2017-08-08 Toyama Chemical Co Ltd Agente de intensificação de efeito de reabilitação pós lesão de nervo compreendendo derivados de éter de alquila ou sal do mesmo
US10238632B2 (en) 2015-06-11 2019-03-26 Fujifilm Toyama Chemical Co., Ltd. Sigma receptor-binding agent
CA3009152C (en) 2015-12-25 2023-08-15 Toyama Chemical Co., Ltd. Tablet comprising 1-(3-(2-(1-benzothiophen-5-yl)ethoxy)propyl)azetidin-3-ol or salt thereof
US20190343796A1 (en) * 2016-12-28 2019-11-14 Fujifilm Toyama Chemical Co., Ltd. Composition for external use
US11541033B2 (en) 2017-06-02 2023-01-03 Fujifilm Toyama Chemical Co., Ltd. Agent for preventing or treating Alzheimer's disease
MX393006B (es) 2017-06-02 2025-03-24 Fujifilm Toyama Chemical Co Ltd Agente para reducir la cantidad de proteina beta amiloide.
KR20190137936A (ko) * 2017-06-02 2019-12-11 후지필름 도야마 케미컬 가부시키가이샤 뇌 위축 예방 또는 치료제
CA3067455C (en) 2017-06-02 2021-11-23 Fujifilm Toyama Chemical Co., Ltd. Agent for preventing or treating spinocerebellar ataxia
JP7227914B2 (ja) 2017-10-30 2023-02-22 富士フイルム富山化学株式会社 エモパミル結合タンパク質結合剤およびその利用

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6294346B1 (en) 1991-07-08 2001-09-25 Neurospheres Holdings, Ltd. Use of multipotent neural stem cells and their progeny for the screening of drugs and other biological agents
JPH05284992A (ja) * 1992-04-14 1993-11-02 Sagami Chem Res Center 神経成長因子産生促進剤及びその製造法
GB9309749D0 (en) * 1993-05-12 1993-06-23 Boots Co Plc Therapeutic agents
JPH07285912A (ja) * 1994-04-19 1995-10-31 Asahi Chem Ind Co Ltd 新規化合物ａｍ５２２１
JP2733207B2 (ja) * 1995-05-18 1998-03-30 工業技術院長 繊維芽細胞成長因子キメラ蛋白質を含有する医薬組成物
AU1506499A (en) * 1997-12-12 1999-07-05 Toyama Chemical Co. Ltd. Alkyl ether derivatives or salts thereof and calcium antagonists containing the same
IL129178A0 (en) * 1999-03-25 2000-02-17 Yeda Res & Dev Induction of nerve generation
SK287673B6 (sk) * 1999-06-11 2011-05-06 Toyama Chemical Co., Ltd Derivát N-alkoxyalkyl-N,N-dialkylamínu, liečivo obsahujúce tento derivát a jeho použitie
GB2367554A (en) * 2000-10-04 2002-04-10 Lilly Co Eli Pharmacologically active amines
US20040030131A1 (en) * 2000-10-04 2004-02-12 Martine Keenan Pharmaceutical compounds
JP4303435B2 (ja) * 2001-02-26 2009-07-29 富山化学工業株式会社 ミトコンドリア機能賦活剤
JP4357802B2 (ja) * 2001-07-05 2009-11-04 武田薬品工業株式会社 ベンゼン環縮合５員複素環式化合物、その製造法および用途
ATE527247T1 (de) * 2001-07-05 2011-10-15 Takeda Pharmaceutical Benzokondensierte 5gliedrige heterocyclische verbindungen, verfahren zu deren herstellung und deren verwendung
JP4905752B2 (ja) * 2001-07-24 2012-03-28 エスティー・ラボ株式会社 揮発性有機塩素化合物センサ
BRPI0213393B8 (pt) * 2001-10-19 2021-05-25 Fujifilm Toyama Chemical Co Ltd derivados de éter alquílico, ou um de seus sais, processo para produzir um derivado de éter alquílico, derivado de alquil-amida, ou um de seus sais, e, composição farmacêutica
JP4537011B2 (ja) * 2002-03-01 2010-09-01 武田薬品工業株式会社 抗うつ剤
HUE041842T2 (hu) * 2002-06-14 2019-05-28 Toyama Chemical Co Ltd Gyógyászati készítmény agymûködés javítására
JP2004256428A (ja) * 2003-02-25 2004-09-16 Science Univ Of Tokyo 神経栄養因子様プリン系化合物含有作用剤
ES2391273T3 (es) * 2003-04-17 2012-11-23 Toyama Chemical Co., Ltd. Agente preventivo/curativo para enfermedades del nervio retiniano que contiene derivados de éter alquílico o sus sales
WO2005032535A1 (ja) * 2003-10-03 2005-04-14 Ono Pharmaceutical Co., Ltd. 神経再生促進剤

Also Published As

Publication number Publication date
PT2011796E (pt) 2014-11-26
US20090093453A1 (en) 2009-04-09
NO20084338L (no) 2008-11-19
BRPI0710239A2 (pt) 2011-08-09
CN101432280B (zh) 2012-11-21
JP2013177410A (ja) 2013-09-09
WO2007125913A1 (ja) 2007-11-08
CN101432280A (zh) 2009-05-13
EP2011796A1 (en) 2009-01-07
SI2011796T1 (sl) 2015-02-27
ES2518371T3 (es) 2014-11-05
NZ571975A (en) 2011-04-29
KR101374593B1 (ko) 2014-03-17
AU2007244409A1 (en) 2007-11-08
KR20080111131A (ko) 2008-12-22
IL194569A (en) 2014-09-30
EP2011796B1 (en) 2014-10-08
ZA200808728B (en) 2010-01-27
JPWO2007125913A1 (ja) 2009-09-10
CA2648898A1 (en) 2007-11-08
MX2008013728A (es) 2009-01-07
NO342153B1 (no) 2018-04-03
JP5695293B2 (ja) 2015-04-01
CA2648898C (en) 2015-01-20
PL2011796T3 (pl) 2015-03-31
EP2011796A4 (en) 2010-07-07
IL194569A0 (en) 2009-08-03
CY1115643T1 (el) 2017-01-04
AU2007244409B2 (en) 2011-12-01

Similar Documents

Publication Publication Date Title
DK2011796T3 (da) Neurogenese-inducer eller terapeutisk middel mod neuropati omfattende alkyletherderivat eller salt deraf
NO2022057I1 (no) Capmatinib or a pharmaceutically acceptable salt thereof
FIC20253005I1 (fi) Seladelpaarin L-lysiinisuola, erityisesti seladelpaari-L-lysiinidihydraatti
NO2025009I1 (no) Oxathiapiprolin or an N-oxide or salt thereof and amisulbrom
FIC20210018I1 (fi) Cenobamat eller ett farmaceutiskt salt därav
FIC20240039I1 (fi) Kapivasertibi, valinnaisesti farmaseuttisesti hyväksyttävän suolan muodossa
NO2018037I1 (no) Simeprevir, eller salt derav, innbefattende natrium-simeprevir
NO2023047I1 (no) Cedazuridine, or a pharmaceutically acceptable salt thereof
NO2019027I1 (no) kobicistat eller et farmasøytisk akseptabelt salt derav
NO2020038I1 (no) Ozanimod, or a pharmaceutically acceptable salt thereof, including the hydrochloride salt
NO2024053I1 (no) aprocitentan eller et farmasøytisk akseptabelt salt derav
NO2019024I1 (no) Brigatinib eller et farmasøytisk akseptabelt salt derav
NL300885I2 (nl) Irinotecansucrosofaatzout
DK2206707T3 (da) Azolcarboxamidforbindelse eller salt deraf
NO2017059I2 (no) ribosiklib eller et farmasøytisk akseptabelt salt derav
DK2068839T3 (da) Farmaceutiske sammensætninger omfattende nilotinib eller salt deraf
NO2016014I2 (no) ceritinib eller farmasøytisk akseptable salter derav
DK2351747T3 (da) Fungicide N-cycloalkylbenzylamidderivater
DK1466912T3 (da) 2-acylaminothiazolderivat eller salt deraf
SI3424932T1 (sl) Boronoftalidi za terapevtsko uporabo
ATE475662T1 (de) Dihydropyrazolopyrimidinonderivate
BRPI0722082A8 (pt) ligantes para imagiologia da inervação cardíaca
ATE469905T1 (de) Pyridopyrimidinonderivate
EP1973405A4 (en) HYDROXYALKYLARYLAMID DERIVATIVES
DK2295414T3 (da) Uracilforbindelse med en hæmmende virkning på human deoxyuridintriphosphatase eller salt deraf